Jonathan Brammer: Clinical Trials

2 trials sponsored by Jonathan Brammer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Recruiting 1
Phase 11Active not recruiting 1

Follow Jonathan Brammer: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Ruxolitinib - T-Cell Large Granular Lymphocyte Leukemia
Phase 2RecruitingJonathan Brammer302023-05-032026-10-01
Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia
Oral Azacitidine - T-Cell Large Granular Lymphocyte Leukemia
Phase 1 / Phase 2Active not recruitingJonathan Brammer112022-06-292026-10-21

Conditions studied

Leukemia, Large Granular Lymphocytic (2)

Interventions

Azacitidine (1)  ·  cc-486 (1)  ·  ruxolitinib (1)

Countries

United States (2)